Malignant pleural mesothelioma: From the bench to the bedside

Respiration

Volumn 83, Issue 6, 2012, Pages 481-493

  Astoul, P ^a,b   Roca, E ^a   Galateau Salle, F ^c   Scherpereel, A ^d,e,f  

^a HÔPITAL NORD   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIV LILLE   (France)

^f INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Diagnosis; Mesothelioma; Pleura; Targeted therapy; Translational research; Treatment; Tumor markers

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; AMATUXIMAB; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CEDIRANIB; CISPLATIN; CRS 207; CYCLOOXYGENASE 2 INHIBITOR; DASATINIB; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; IMMUNOTOXIN; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NVP AEW 541; PACLITAXEL; PEMETREXED; PROTEIN BER EP4; RALTITREXED; RAPAMYCIN; SEMAXANIB; SOLUBLE MESOTHELIN RELATED PROTEIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB;

ANGIOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME ABERRATION; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; GENE SILENCING; HUMAN; LUNG NON SMALL CELL CANCER; MESOTHELIUM CELL; OUTCOME ASSESSMENT; PATIENT CARE; PLEURA MESOTHELIOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; TRANSLATIONAL RESEARCH; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; NEOVASCULARIZATION, PHYSIOLOGIC; PLEURAL NEOPLASMS; PROGNOSIS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA-BINDING PROTEINS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84862749245     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000339259     Document Type: Review

References (164)

1. Yang H, Bocchetta M, Kroczynska B, et al: TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006; 103: 10397-10402.
2. Zucali PA, Ceresoli GL, De Vincenzo, et al: Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 2011; 37: 543-558.
3. Xu A, Wu LJ, Santella RM, et al: Role of oxyradicals in mutagenicity and DNA damage induced by crocidolite asbestos in mammalian cells. Cancer Res 1999; 59: 5922-5926.
4. Ramos-Nino ME, Timblin CR, Mossman BT: Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 2002; 62: 6065-6069.
5. Liu Z, Klominek J: Chemotaxis and chemokinesis of malignant cells to multiple growths factors. Anticancer Res 2004; 24: 1625-16230.
6. Strizzi L, Catalano A, Vianale G, et al: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001; 193: 468-475.
7. Galffy G, Mohammed KA, Downling PA, et al: Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999; 59: 367-371.
8. Carbone M, Kratzke RA, Testa JR: The pathogenesis of mesothelioma. Semin Oncol 2002; 29: 2-17.
9. Murthy SS, Testa JR: Asbestos, chromosomal deletions, and tumor suppressor gene alterations in humal malignant mesothelioma. J Cell Physiol 1999; 180: 150-157.
10. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 2: 107-116.
11. Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
12. Cao XX, Mohuiddin I, Ece F, et al: Histone deacetylase inhibitor downregulation of bclxl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 2001; 25: 562-568.
13. Frew AJ, Johnstone RW, Bolden JE: Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280: 125-133.
14. Cheng JQ, Lee WC, Klein MA, et al: Frequent mutations of NF2 and allellic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 1999; 24: 238-242.
15. Poulikakos PI, Xiao GH, Gallagher R, et al: Re-expression of the tumor-suppressor NF2/ merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006; 25: 5960-5968.
16. Thurneysen C, Opitz I, Kurtz S, et al: Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009; 64: 140-147.
17. Fleury-Feith J, Lecomte C, Renier A, et al: Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 2003; 22: 3799-3805.
18. Deguen B, Goutebroze L, Giovannini M, et al: Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer 1998; 77: 554-560.
19. Lopez-Lago MA, Okada T, Murillo MM, et al: Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009; 64: 140-147.
20. van der Bij S, Schaake E, Koffijberg H, et al: Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 2011; 104: 1325-1333.
21. Lyons-Boudreaux V, Mody DR, Zhai J, et al: Cytologic malignancy versus benignancy: how useful are the 'newer' markers in body fluid cytology? Arch Pathol Lab Med 2008; 132: 23-28.
22. Pass HI, Lott D, Lonardo F, et al: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564-1573.
23. Holloway AJ, Diyagama DS, Opeskin K, et al: A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res 2006; 12: 5129-5135.
24. Scherpereel A, Grigoriu B, Conti M, et al: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 1155-1160.
25. Creaney J, Yeoman D, Demelker Y, et al: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008; 3: 851-857.
26. Husain AN, Colby TV, Ordóñez NG, et al: Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-1331.
27. Miles D, Papazisis K: Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer (review). Clin Breast Cancer 2003; 3(suppl 4):S134-S138.
28. Wierecky J, Mueller M, Brossart P: Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 2006; 55: 63-67.
29. Kato Y, Tsuta K, Seki K, et al: Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007; 20: 215-220.
30. Shi M, Fraire AE, Chu P, et al: Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 2011; 35: 878-882.
31. Biesheuvel CJ, Vergouwe Y, Oudega R, et al: Advantages of the nested case-control design in diagnostic research. BMC Med Res Methodol 2008; 8: 48.
32. Rutjes AW, Reitsma JB, Vandenbroucke JP, et al: Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem 2005; 51: 1335-1341.
33. Moons KG: Criteria for scientific evaluation of novel markers: a perspective. Clin Chem 2010; 56: 537-541.
34. Riley RD, Sauerbrei W, Altman DG: Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009; 100: 1219-1229.
35. Cristaudo A, Foddis R, Vivaldi A, et al: Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 17: 5076-5081.
36. López-Ríos F, Chuai S, Flores R, et al: Global gene expression profiling of pleural mesothelioma: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006; 66: 2970-2979.
37. Borczuk AC, Taub RN, Hesdorffer M, et al: P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res 2005; 50: 189-198.
38. Edwards JG, Swinson DE, Jones JL, et al: Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003; 124: 1916-1923.
39. Kokturk N, Firat P, Akay H, et al: Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma. Lung Cancer 2005; 50: 189-198.
40. Demirag F, Unsal E, Yilmaz A, et al: Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005; 128: 3382-3387.
41. Kumar-Sing S, Weyler J, Martin MJ, et al: Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999; 189: 72-78.
42. Opitz I, Soltermann A, Abaecherli M, et al: PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008; 33: 502-506.
43. Gordon GJ, Rockwell GN, Godfrey PA, et al: Validation of genomic-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2005; 11: 4406-4414.
44. Glinsky GV, Berezovska O, Glinskii AB, et al: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-1521.
45. Pass H, Goparaju C, Ivanov S, et al: HsamiR29c * is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 2010; 70: 1916-1924.
46. Levallet G, Vaisse-Lesteven M, Le Stang N, et al: Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group. J Thorac Oncol 2012; 7: 599-606.
47. Sigmond J, Backus HH, Wouters D, et al: Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003; 66: 431-438.
48. Ceppi P, Volante M, Ferrero A, et al: Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008; 14: 1059-1064.
49. Bepler G, Sommers KE, Cantor A, et al: Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008; 3: 1112-1118.
50. Righi L, Papotti MG, Ceppi P, et al: Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010; 28: 1534-1539.
51. Zucali PA, Giovannetti E, Destro A, et al: Thymidylate synthase and excision repair cross-complementing group 1 as predictors of responsiveness in patients with malignant pleural mesothelioma treated with pemetrexed and carboplatin. Clin Cancer Res 2011; 17: 2581-2590.
52. Pinto C, Ardizzoni A, Betta PG, et al: Expert opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma. Am J Clin Oncol 2011; 34: 99-109.
53. Scherpereel A, Astoul P, Baas P, et al: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-495.
54. Yarden Y: The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(suppl 4):S3-S8.
55. Destro A, Ceresoli GL, Falleni M, et al: EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006; 51: 207-215.
56. Herndon JE, Green MR, Chahinian AP, et al: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-731.
57. Govindan R, Kratzke RA, Herndon JE 2nd, et al: Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005; 11: 2300-2304.
58. Garland LL, Rankin C, Gandara DR, et al: Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007; 25: 2406-2413.
59. Cortese JF, Gowda AL, Wali A, et al: Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 2006; 118: 521-522.
60. Gaafar R, Bahnassy A, Abdelsalam I, et al: Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 2010; 70: 43-50.
61. Okuda K, Sasaki H, Kawano O, et al: Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 2008; 134: 1105-1111.
62. O'Byrne KJ, Edwards JG, Waller DA: Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 2004; 45(suppl 1):S45-S48.
63. Dazzi H, Hasleton PS, Thatcher N, et al: Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990; 61: 924-926.
64. Edwards JG, Swinson DE, Jones JL, et al: EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006; 54: 399-407.
65. Kono SA, Marshall ME, Ware KE, et al: The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat 2009; 12: 95-102.
66. Eyzaguirre A, Buck E, Iwata K, et al: Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies. Target Oncol 2008; 3: 235-243.
67. Engelman JA, Janne PA: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895-2899.
68. Jagadeeswaran R, Ma PC, Seiwert TY, et al: Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006; 66: 352-361.
69. Whitson BA, Jacobson BA, Frizelle S, et al: Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. Ann Thorac Surg 2006; 82: 996-1001.
70. Kai K, D'Costa S, Sills RC, et al: Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009; 278: 49-55.
71. Dannenberg AJ, Lippman SM, Mann JR, et al: Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254-266.
72. Hull MA: Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? Eur J Cancer 2005; 41: 1854-1863.
73. Amir M, Agarwal HK: Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie 2005; 60: 563-570.
74. Gasparini G, Longo R, Sarmiento R, Morabito A: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003; 4: 605-615.
75. Baldi A, Santini D, Vasaturo F, et al: Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 2004; 59: 428-433.
76. Edwards JG, Faux SP, Plummer SM, et al: Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002; 8: 1857-1862.
77. O'Kane SL, Cawkwell L, Campbell A, Lind MJ: Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer 2005; 41: 1645-1648.
78. Catalano A, Graciotti L, Rinaldi L, et al: Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 2004; 109: 322-328.
79. O'Kane SL, Eagle GL, Greenman J, et al: COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer 2010; 67: 160-165.
80. Kitamura F, Araki S, Tanigawa T, et al: Assessment of mutations of Ha- and Ki-ras oncogenes and the p53 suppressor gene in seven malignant mesothelioma patients exposed to asbestos-PCR-SSCP and sequencing analyses of paraffin-embedded primary tumors. Ind Health 1998; 36: 52-56.
81. Kitamura F, Araki S, Suzuki Y, et al: Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients. Ind Health 2002; 40: 175-181.
82. Ni Z, Liu Y, Keshava N, et al: Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos. Mutat Res 2000; 468: 87-92.
83. Dote H, Tsukuda K, Toyooka S, et al: Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP. Oncol Rep 2004; 11: 361-363.
84. Suzuki Y, Murakami H, Kawaguchi K, et al: Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2009; 2: 181-188.
85. Altomare DA, You H, Xiao GH, et al: Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005; 24: 6080-6089.
86. Ohta Y, Shridhar V, Bright RK, et al: VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999; 81: 54-61.
87. Dowell J, Kindler H: Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am 2005; 19: 1137-1145.
88. Yasumitsu A, Tabata C, Tabata R, et al: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 2010; 5: 479-483.
89. Jackman DM, Kindler HL, Yeap BY, et al: Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008; 113: 808-814.
90. Jahan T, Gu L, Kratzke R, et al: Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2011, E-pub ahead of print.
91. Mitchell CL, O'Connor JP, Roberts C, et al: A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol 2011; 68: 631-641.
92. Drevs J, Siegert P, Medinger M, et al: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 3045-3054.
93. Matulonis UA, Berlin S, Ivy P, Tyburski K, et al: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27: 5601-5606.
94. Garland L, Chansky K, Wosniak A, et al: Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 2011; 6: 1938-1945.
95. Morabito A, De Maio E, Di Maio M, et al: Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006; 11: 753-764.
96. Baas P, Boogerd W, Dalesio O, et al: Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005; 48: 291-296.
97. Dubey S, Jänne PA, Krug L, et al: A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010; 5: 1655-1661.
98. Richly H, Henning BF, Kupsch P, et al: Results of a phase I trial of sorafenib (BAY43-9006) in combination with doxorubicin in patients with refractory solid tumours. Ann Oncol 2006; 17: 866-873.
99. König JE, Tolnay E, Wiethege T, Müller KM: Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration 2000;67:36-40.
100. Klabatsa A, Sheaff MT, Steele JP, et al: Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1 alpha) in malignant pleural mesothelioma (MPM). Lung Cancer 2006; 51: 53-59.
101. Millward M, Parnis F, Byrne M, et al: Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma (abstract 912). Proc Am Soc Clin Oncol 2003; 22: 912.
102. Villano J, Husain A, Stadler M, Hanson L, Vogelzang N, Kindler H, et al: A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 2004; 22: 14.
103. Mathy A, Baas P, Dalesio O, et al: Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50: 83-86.
104. Porta C, Mutti L, Tassi G: Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007; 59: 149-150.
105. Bertino P, Porta C, Barbone D, et al: Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007; 62: 690-695.
106. Edwards JG, Cox G, Andi A, et al: Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001; 85: 863-868.
107. Filiberti R, Marroni P, Neri M, et al: Serum PDGF-AB in pleural mesothelioma. Tumour Biol 2005; 26: 221-226.
108. Vogelzang NJ, Porta C, Mutti L: New agents in the management of advanced mesothelioma. Semin Oncol 2005; 32: 336-350.
109. Arber DA, Tamayo R, Weiss LM: Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998; 29: 498-504.
110. Pietras K, Rubin K, Sjöblom T, et al: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62: 5476-5484.
111. Ali Y, Lin Y, Gharibo MM, et al: Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 5876-5882.
112. Tsao AS, He D, Saigal B, et al: Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007; 6: 1962-1972.
113. Dudek A, Pang H, Kratzke A: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma. J Natl Cancer Inst 2010; 28: 15.
114. Ramos-Nino ME, Testa JR, Altomare DA, et al: Cellular and molecular parameters of mesothelioma. J Cell Biochem 2006; 98: 723-734.
115. Raymond E, Alexandre J, Faivre S, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-2347.
116. Hartman ML, Esposito JM, Yeap BY, et al: Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J Thorac Cardiovasc Surg 2010; 139: 1233-1240.
117. Chang K, Pai LH, Pass H, et al: Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992; 16: 259-268.
118. Chang K, Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: 136-140.
119. Hassan R, Bera T, Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004; 10: 3937-3942.
120. Hassan R, Schweizer C, Lu KF, et al: Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy. Lung Cancer 2010; 68: 455-459.
121. Greillier L, Baas P, Welch JJ, et al: Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther 2008; 12: 375-390.
122. Hassan R, Broaddus VC, Wilson S, et al: Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 2007; 13: 7166-7171.
123. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al: Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002: 20: 274-281.
124. Mittelman A, Puccio C, Gafney E, et al: A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion. Invest New Drugs 1992; 10: 183-190.
125. Lejeune FJ, Lienard D, Matter M, et al: Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006; 6: 6.
126. Gregorc V, Zucali PA, Santoro A, et al: Phase II study of asparagine-glycine arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010; 28: 2604-2611.
127. Kelly WK, O'Connor OA, Krug LM, et al: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923-3931.
128. Paik PK, Krug LM: Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 2010; 5: 275-279.
129. Ramalingam SS, Parise RA, Ramanathan RK, et al: Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007; 13: 3605-3610.
130. Ramalingam SS, Belani CP, Ruel C, et al: Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009; 4: 97-101.
131. Marks PA, Richon VM, Miller T, et al: Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-168.
132. Scherpereel A, Berghmans T, Lafitte JJ, et al: Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 2011; 37: 129-135.
133. Shapiro GI, Tibes R, Gordon MS, et al: Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 3431-3442.
134. Mulatero CW, Penson RT, Papamichael D, et al: A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 2001; 31: 67-72.
135. Nowak AK, Lake RA, Kindler HL, et al: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002; 29: 82-96.
136. Astoul P, Picat-Joossen D, Viallat JR, et al: Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998; 83: 2099-2104.
137. Caminschi I, Venetsanakos E, Leong CC, et al: Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol 1998; 19: 738-746.
138. Fennell DA, Chacko A, Mutti L: BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008; 27: 1189-1197.
139. Sartore-Bianchi A, Gasparri F, Galvani A, et al: Bortezomib inhibits nuclear factorkappa B-dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007; 13: 5942-5951.
140. Gordon GJ, Mani M, Maulik G, et al: Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008; 61: 549-558.
141. Trandafir L, Ruffié P, Borel C, et al: Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur J Cancer 1997; 33: 1900-1902.
142. Upham JW, Musk AW, van Hazel G, et al: Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust NZ J Med 1993; 23: 683-687.
143. Parra HS, Tixi L, Latteri F, et al: Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 2001; 92: 650-656.
144. Halme M, Knuuttila A, Vehmas T, et al: High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 1999; 80: 1781-1785.
145. Bretti S, Berruti A, Dogliotti L, et al: Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori 1998; 84: 558-561.
146. Hegmans JP, Hemmes A, Aerts JG, et al: Immunotherapy of murine malignant mesothelioma using tumour lysate-pulsed dendritic cells. Am J Respir Crit Care Med 2005; 171: 1168-1177.
147. Hegmans JP, Hemmes A, Hammad H, et al: Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006; 27: 1086-1095.
148. Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG: Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010; 181: 1383-1390.
149. Haas AR, Sterman DH: Novel intrapleural therapies for malignant diseases. Respiration 2012;83:277-292.
150. Tilleman TR, Richards WG, Zellos L, et al: Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009; 138: 405-411.
151. Sterman DH, Treat J, Litzky LA, et al: Adenovirus- mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9: 1083-1092.
152. Molnar-Kimber KL, Sterman DH, Chang M, et al: Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998; 9: 2121-2133.
153. Sterman DH, Recio A, Vachani A, et al: Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444-7453.
154. Sterman DH, Recio A, Carroll RG, et al: A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13: 4456-4466.
155. Hassan R, Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44: 46-53.
156. Hassan R, Zhang J, Pastan I: Antibody-based treatment for mesothelioma: clinical trials and laboratory studies. Lung Cancer 2006; 54:S13.
157. Hassan R, Bullock S, Premkumar A, et al: Phase I study of SS1P, a recombinant antimesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13: 5144-5149.
158. Li Q, Verschraegen CF, Mendoza J, et al: Cytotoxic activity of the recombinant antimesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res 2004; 24: 1327-1335.
159. Armstrong DK, Laheru D, Ma WW, et al: A phase I study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma, and ovarian adenocarcinoma (abstract). J Clin Oncol 2007; 25: 615s.
160. Brockstedt DG, Giedlin MA, Leong ML, et al: Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA 2004; 101: 13832-13837.
161. Thomas AM, Santarsiero LM, Lutz ER, et al: Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004; 200: 297-306.
162. Hassan R, Ebel W, Routhier EL, et al: Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007; 7: 20.
163. Jantz MA, Antony VA: Pathophysiology of the pleura. Respiration 2008;75:121-133.
164. Froudarakis ME: Pleural diseases in the molecular era - time for more answers: introduction. Respiration 2012;83:2-4.